Valmor 50 Tablet

About Valmor 50 24 mg + 26 mg Tablet

Valmor 50 is a heart failure medicine that combines sacubitril and valsartan to help the heart pump better and reduce strain. It is used in adults with chronic heart failure and in children aged one year and older.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 3 of them have a lower unit price than Valmor 50. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is Valmor 50 24 mg + 26 mg Tablet?

Valmor 50 is a tablet containing sacubitril and valsartan. It belongs to a group of medicines used to treat heart failure. In heart failure, the heart does not pump blood as well as it should. This medicine works in two ways: sacubitril increases the levels of natural peptides that help the heart and blood vessels, while valsartan blocks the effects of a substance called angiotensin II that can raise blood pressure and strain the heart. Together, they help reduce the risk of death and hospitalization from heart failure in adults with reduced ejection fraction, and treat symptoms in children aged one year and older.

Uses of Valmor 50

Valmor 50 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Your doctor will decide if this medicine is suitable for you or your child.

How to use Valmor 50

Take Valmor 50 exactly as your doctor tells you. The dose and how often you take it will be decided by your doctor based on your condition and other medicines you take. Swallow the tablet whole with water. Do not change the dose or stop taking it without talking to your doctor. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Valmor 50

Common side effects include angioedema (swelling of the face, lips, tongue, or throat), low blood pressure, impaired kidney function, high potassium levels, cough, and dizziness. Call your doctor right away if you have swelling of the face, lips, tongue, or throat, difficulty breathing, or if you feel very dizzy or faint. These could be signs of a serious reaction.

Safety and precautions

Before taking Valmor 50, tell your doctor if you have a history of angioedema or if you are allergic to any of its ingredients. Do not take it with ACE inhibitors or aliskiren if you have diabetes. Your doctor will monitor your kidney function and potassium levels. This medicine is not recommended in severe liver impairment. It is not known if it is safe during pregnancy; ask your doctor. The safety and effectiveness in children under one year have not been established. Elderly patients can take it without dose adjustment.

Frequently asked questions

How should Valmor 50 be taken?

The dose and how often you take Valmor 50 will be decided by your doctor. Take it exactly as prescribed, with or without food. Do not change the dose or stop taking it without talking to your doctor first.

What is Valmor 50 used for and what kind of medicine is it?

Valmor 50 is used to treat chronic heart failure in adults with reduced ejection fraction and in children aged one year and older with symptomatic heart failure. It is a combination of sacubitril and valsartan, which work together to help the heart.

What side effects should I watch for and when should I call the doctor?

Watch for swelling of the face, lips, tongue, or throat, difficulty breathing, severe dizziness, or fainting. These could be signs of a serious reaction. Call your doctor right away if you notice any of these, or if you have other side effects that bother you.

Who should not take Valmor 50?

Do not take Valmor 50 if you have had angioedema related to an ACE inhibitor or ARB, or if you take an ACE inhibitor. Talk to your doctor about other conditions, such as kidney or liver problems, or if you are pregnant or breastfeeding.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.